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Mesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitors and are capable of differen-
tiating into several tissues of mesenchymal origin. We have shown that bone marrow-derived MSCs from both 
SLE patients and lupus-prone MRL/lpr mice are defective structurally and functionally. Here we observe the 
long-term safety and efficacy of allogeneic MSC transplantation (MSCT) in treatment-resistant SLE patients. 
Eighty-seven patients with persistently active SLE who were refractory to standard treatment or had life-
threatening visceral involvement were enrolled. Allogeneic bone marrow or umbilical cord-derived MSCs 
were harvested and infused intravenously (1 × 106 cells/kg of body weight). Primary outcomes were rates of 
survival, disease remission and relapse, as well as transplantation-related adverse events. Secondary outcomes 
included SLE disease activity index (SLEDAI) and serologic features. During the 4-year follow-up and with a 
mean follow-up period of 27 months, the overall rate of survival was 94% (82/87). Complete clinical remission 
rate was 28% at 1 year (23/83), 31% at 2 years (12/39), 42% at 3 years (5/12), and 50% at 4 years (3/6). Rates 
of relapse were 12% (10/83) at 1 year, 18% (7/39) at 2 years, 17% (2/12) at 3 years, and 17% (1/6) at 4 years. 
The overall rate of relapse was 23% (20/87). Disease activity declined as revealed by significant changes in the 
SLEDAI score, levels of serum autoantibodies, albumin, and complements. A total of five patients (6%) died 
after MSCT from non-treatment-related events in the 4-year follow-up, and no transplantation-related adverse 
event was observed. Allogeneic MSCT resulted in the induction of clinical remission and improvement in 
organ dysfunction in drug-resistant SLE patients.
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modalities may cause severe side effects such as infection, 
ovarian failure, and secondary malignancy (14,23,26), 
which remain as the important causes of mortality in SLE 
patients. Thus, more effective, but less toxic, treatments 
are needed.
Mesenchymal stem cells (MSCs), multipotential non-
hematopoietic progenitors, can be isolated from various 
tissues and are capable of differentiating into several tis-
sues of mesenchymal origin (4,15). These pluripotent cells 
can also differentiate into endoderm and neuroectoderm 
lineages, including neurons, hepatocytes, and cardiocytes 
INTRODUCTION
Systemic lupus erythematosus (SLE), a chronic auto-
immune disease with significant morbidity and mortality, 
is characterized by highly diverse clinical manifestations 
and can affect any organs of the body (25). The conventio nal 
treatment of SLE mainly relies on high doses of cortico-
steroids, cyclophosphamide (CYC), and other immuno-
suppressive and biological agents. Although these drugs 
have led to markedly improved outcome in SLE (5,13), 
disease control remains unsatisfactory in a subset of 
patients (10,20). Moreover, the conventional therapeutic 
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(7,27,28). MSCs can modulate allogeneic immune cell 
responses including T-cells, B-cells, natural killer (NK) 
cells, and dendritic cells (12,22,30). In addition, inher-
ently low immunogenicity due to lack of costimulatory 
molecule expression enables MSCs to escape alloanti-
gen recognition. These properties make MSCs promising 
candidate cells for preventing rejection in organ trans-
plantation and also as a promising potential treatment of 
autoimmune disease, including SLE.
In previous investigations, we showed that bone 
 marrow-derived mesenchymal stem cells (BM-MSCs) 
from both SLE patients and lupus-prone Murphy Roths 
Large-lymphoproliferation spontaneous mutation (MRL/
lpr) mice are defective structurally and functionally 
(32,34), which has been also confirmed by other studies 
(6,24). We therefore hypothesized that defects in lupus 
MSCs may contribute to disease pathology and conse-
quently present a novel therapy target. If this hypothesis 
is true, then allogeneic, rather than autologous, MSC 
transplantation might prove to be an effective treatment 
for SLE. Consistent with our hypothesis, Carrion et al. 
showed that autologous bone marrow MSC treatment 
did not improve disease activity in two SLE patients (3). 
Consequently, after our preclinical assessments verified 
the potential therapeutic effects and possible mecha-
nisms of human BM-MSC transplantation (BM-MSCT) on 
ameliorating autoimmune progression in MRL/lpr mice 
(32,35), we initiated the studies of allogeneic MSCT for 
lupus treatment, and the results of two short-term follow- 
up studies were encouraging (19,33), but the small number 
of patients and the short-term follow-up limit any conclu-
sions regarding long-term safety and efficacy. We there-
fore carried out this 4-year follow-up study that included 
87 severe and refractory SLE patients.
MATERIALS AND METHODS
Study Design and Patient Enrollment
From March 2007 to April 2010, 87 SLE patients 
refractory to standard therapies were enrolled in an allo-
geneic MSCT trial at the Nanjing Drum Tower Hospital 
after signing an informed consent (Table 1). The study 
was approved by the Ethics Committee at The Drum 
Tower Hospital of Nanjing University Medical School. 
All enrolled patients had fulfilled at least 4 of 11 American 
College of Rheumatology criteria for the classification 
of SLE (29). The eligibility criteria included progressive 
and active disease with the modified Safety of Estrogens 
in Lupus Erythematosus National Assessment version of 
the Systemic Lupus Erythematosus Disease Activity Index 
(SELENA-SLEDAI) score of ≥8 (1). All the patients 
were unresponsive to conventional immunosuppres-
sive drugs [CYC (Jiangsu Hengrui Medicine, Co. Ltd., 
Jiangsu, China) 500–1,000 mg/m2/month, mycophenolate 
mofetil 2 g/day (F. Hoffmann-La Roche Ltd., Shanghai, 
China), azathioprine 200 mg/day, leflunomide 20 mg/day 
(Soochow Changzheng-Cinkate Corporation Co. Ltd., 
Soochow, China), alone or in combination for more than 6 
months] or had continuing requirement for daily dosage of 
≥20 mg of prednisone (Tianjin Pharmaceutical Group Co., 
Ltd., Tianjin, China) or its equivalent. Patients were also 
included if they underwent severe and refractory cytopenia, 
although with a SELENA-SLEDAI score of <8. Patients 
were excluded from this study if they had uncontrolled 
infection, mean pulmonary artery pressure of ≥50 mmHg, 
failure of one or more organs, pregnant, or lactating.
MSC Transplantation
Bone marrow MSCs were isolated from bone mar-
row aspirates obtained from healthy donors (26 donors: 
11 female and 15 female, average age 30.4 ± 9.0 years; 
range 16–43 years) with informed consent (32). Briefly, 
20 ml of bone marrow was aspirated on the posterior iliac 
Table 1. Patient Demographics and Pretransplantation History
Variable No. of Patients
Age (year) 31.5 (12–56)
Disease duration (month) 37.5 (2–264)
Sex (female/male) 80/7
Race (Asian/other) 87/0
Renal involvement [n (%)] 73 (84)
Abnormal urine protein 
[n (mean ± SD) g/24 h]
73 (2.71 ± 1.19)
Abnormal serum creatinine 
[n (mean ± SD) mg/dl]
31 (2.29 ± 1.11)
Abnormal serum urea nitrogen 
[n (mean ± SD) mmol/l]
31 (18.27 ± 9.45)
GFR [n (%)]
>100 ml/min 10 (15.87)
≥60 to ≤100 ml/min 18 (28.57)
≥30 to ≤60 ml/min 28 (44.44)
















Other 1 patient each: rituximab, 
tacrolimus
GFR, glomerular filtration rate.
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crest. Bone marrow mononuclear cells were separated by 
Ficoll (Tianjin Haoyang Biotech, Inc., Tianjin, China) 
density centrifugation. Mononuclear cells were cultured 
in a 175-cm2 flask (Corning, Inc., Corning, NY, USA) 
with low-glucose Dulbecco’s modified Eagle’s medium 
(DMEM-LG; Gibco, Gaithersburg, MD, USA) contain-
ing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, 
USA) and 1% penicillin–streptomycin (Gibco) in a humid-
ified incubator at 37°C under 5% CO2. Nonadherent cells 
were removed when the medium was exchanged at the 
third day. When the primary MSCs had expanded to 80% 
confluence, they were harvested and expanded to reach 
treatment dose based on the body weight of the recipient. 
Umbilical cord (UC) MSCs (11 females, 5 males) were 
prepared by the Stem Cell Center of Jiangsu Province. 
Fresh UC was obtained from 16 informed healthy moth-
ers (ages 20–30 years) in local maternity hospitals after 
normal deliveries (33). The cords were rinsed by phos-
phate-buffered saline (PBS; Wuhan Boster Biological 
Technology, Co. Ltd., Wuhan, China) in penicillin and 
streptomycin, the cord blood being removed during this 
process. The washed cords were cut into 1-mm2-sized 
pieces and floated in DMEM-LG containing 10% FBS. 
The pieces of cord were subsequently incubated at 37°C 
in humid air with 5% CO2. Nonadherent cells were removed 
by washing. The medium was replaced every 3 days after 
the initial plating. When well-developed colonies of fibro-
blast-like cells appeared after 10 days, the cultures were 
trypsinized (Gibco) and passaged into a new flask for fur-
ther expansion. At about 80–85% confluency, the adher-
ent cells were detached by treatment with 0.125% trypsin 
and 0.1% EDTA (Gibco). The cells were analyzed for the 
following surface markers by flow cytometry: cluster of 
differentiation 73 (CD73), CD105, CD90, CD29, human 
leukocyte antigen (HLA)-DR, CD45, CD34, CD14, and 
CD79 (all the antibodies were from eBioscience, Inc., 
San Diego, CA, USA).
To induce adipogenic differentiation, MSCs were cul-
tured in culture medium supplemented with 1 × 106 M 
dexamethasone, 0.02 mg/ml indomethacin, and 10 μg/ml 
insulin (all Sigma-Aldrich). After 12 days of culture, cell 
differentiation into adipocytes was confirmed by Oil Red 
O staining (Sigma-Aldrich).
To induce osteogenic differentiation, adherent cells 
were grown at 3 × 104 cells/cm2 in culture medium with 
10−7 M dexamethasone, 50 μg/ml ascorbic acid, and 
10 mM b-glycerophosphate (all Sigma-Aldrich). After 
21 days of culture, calcium deposits were detected by 
Alizarin Red staining (Sigma-Aldrich).
Criteria for release of MSCs for clinical use included 
absence of visible clumps, spindle-shaped morphology, and 
absence of contamination by pathogens (as documented by 
aerobic and anaerobic cultures) as well as by virus for hep-
atitis B surface antigen, hepatitis B core antibody, hepatitis 
C virus antibody, human immunodeficiency virus antibod-
ies I and II, cytomegalovirus IgM, and syphilis antibody 
[as determined by enzyme-linked immunosorbent assays 
(ELISA); Dakewe Biotech Inc., Co. Ltd., Shenzhen, 
China], cell viability greater than 92% [as determined by 
trypan blue (Sigma-Aldrich, St. Louis, MO, USA) testing]. 
We used good manufacturing practice (GMP) conditions 
and clinical-grade reagents for preparation of the cells. The 
trial was conducted in compliance with current good clini-
cal practice standards and in accordance with the principles 
set forth under the Declaration of Helsinki (1989).
Before allogeneic MSC treatment, patients were 
administered with CYC (10 mg/kg/day; Jiangsu Hengrui 
Medicine, Co. Ltd.) intravenously on days −4, −3, and 
−2 to inhibit active lymphocytes responses. Serum lev-
els of albumin and creatinine were detected by automatic 
biochemical analyzer (Beckman Coulter, Inc., Brea, CA, 
USA), with normal ranges from 3.5 to 5.5 g/dl for albu-
min and from 0.5 to 1.2 mg/dl for creatinine, respectively. 
White blood cell number was detected by automatic cell 
analyzer (Hanfang Medical Instrument, Co. Ltd., Wuhan, 
China) and with 4,000–10,000/μl as a normal range. If the 
patient underwent severe baseline disease condition such 
as low serum albumin (<2.5 g/dl), or high serum creati-
nine (>3.4 mg/dl), or severe leucopenia (white blood cell 
count < 2,000/μl), the dose of CYC would be discontinued. 
All the patients received a single intravenous infusion of 
BM- or UC-derived MSCs (1 × 106 cells/kg of body weight 
per infusion). All the infused MSCs were derived from 
passage 2 to passage 5. Multiple infusions of MSCs were 
permitted if disease activity was not controlled satisfac-
torily or with lupus relapse, employing the same dose 
(but not necessarily the same source) of allogeneic MSCs 
each infusion.
Assessment
After MSCT, all patients returned for scheduled 
follow-up at 1, 3, 6, and 12 months and then yearly there-
after. Physical examinations, including but not limited 
to temperature, blood pressures, pulse, swelling and 
pain of joints, myodynamia, and erythema, were per-
formed. Serologic tests, including serum levels of crea-
tinine, albumin, urea nitrogen, protein [all by automatic 
biochemical analyzer (Beckman Coulter)], anti- double-
stranded DNA (dsDNA), and antinuclear antibody (ANA) 
(both by ELISA, Euroimmun Medical Laboratory Diag-
nostics Stock Company, Lubeck, Germany) were deter-
mined at each visit time. In addition, regular blood and 
urine tests were also assessed by automatic analyzer 
(Hanfang Medical Instrument, Co. Ltd.). Technetium-99m- 
diethylenetriaminepentacetic acid (99mTc-DTPA; 6–7 mIU; 
Nanjing Shengke Biotech. Co. Ltd., Nanjing, China) was 
infused intravenously into the patients and then the speed 
and quantity of its clearance were measured and collected 
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dynamically. Glomerular filtration rate (GFR) was cal-
culated by analyzing the collected images and data. 
Primary outcomes were overall survival and disease 
remission. Complete clinical remission was defined as 
SELENA-SLEDAI score of <3 and steroid requirement 
of £10 mg/day of prednisone or its equivalent, combined 
with British Isles Lupus Assessment Group (BILAG) D 
scores or better in all organs but not hematological system 
(11,21). Complete remission for hematological system 
was defined as white blood cell count > 4,000/μl, hemo-
globin > 11 g/dl, platelet count > 100,000/μl, and steroid 
maintenance £ 10 mg/day of prednisone or its equivalent. 
Disease relapse was defined as an increase in SELENA-
SLEDAI score of ³3 from the previous visit or experience 
one new domain with a BILAG A score or two new domains 
with a BILAG B score after a previous response (11,21). 
Secondary characteristics included SELENA-SLEDAI 
score, lupus serologic changes, systemic evaluations such as 
renal functional indexes, and hematological involvements. 
Transplantation-related mortality included all deaths asso-
ciated with MSC transplantation, except those related to 
recurrence of underlying disease. The investigators assessed 
and recorded adverse events and their severity throughout 
the study.
Statistical Analysis
Rates of overall survival, complete remission, and 
disease relapse at different visit times were analyzed by 
a Kaplan–Meier survival curve. Significance of influen-
tial factors for survival was assessed by Cox regression. 
Pairwise comparisons of pre- and post-MSCT variables 
were analyzed by paired t test analysis. Serial data were 
compared within and between groups by repeated mea-
sures one-way analysis of variance (ANOVA, with or 
without CYC pretreatment, BM- or UC-derived MSC 
infusion), all using statistical software (SPSS 13.0; IBM, 
Armonk, NY, USA). Statistical significance was set at 
p < 0.05 and was adjusted by the Bonferroni method to 
allow for multiple comparisons.
RESULTS
Cell Characteristics
Immunophenotype analysis indicated that the cultured 
MSCs had high expression of CD73, CD105, CD90, 
and CD29 (>90%) and low expression of CD45, CD34, 
CD14, CD79, and HLA-DR (<2%). In vitro osteogenic 
and adipogenic induction of MSCs was also confirmed.
Participant Characteristics
Eighty-seven patients were enrolled in this trial, 
and all patients underwent MSCT. The mean follow-up 
period was 27 months (range 12–48 months). The patient 
demographics and medication history are shown in Table 1. 
 Fifty-one patients (59%) were given intravenous CYC 
for pretreatment before MSC infusion, and 36 (41%) 
patients received no CYC. At the time of data collection, 
69 patients had received a single MSCT (23 from BM 
and 46 from UC), and the other 18 had received multiple 
MSCT (initially 3 from BM and 15 from UC).
Clinical Outcomes
With a mean follow-up period of 27 months, the over-
all survival rate for all patients was 94% (82/87). Survival 
rate was not correlated with disease duration (p = 0.60, 
95% confidence interval = 0.99–1.01), initial SELENA-
SLEDAI score (p = 0.24, 95% confidence interval = 0.96–
1.20), BM- or UC-derived MSC infusions (p = 0.93, 95% 
confidence interval = 0.11–11.34), or CYC conditioning 
regimen (p = 0.22, 95% confidence interval = 0.04–2.08) 
by Cox regression. The probability of complete clini-
cal remission was 28% at 1 year (23/83), 31% at 2 years 
(12/39), 42% at 3 years (5/12), and 50% at 4 years (3/6), 
respectively (Fig. 1). The longest continuous duration of 
remission was 42 months. Time to remission varied from 
3 to 24 months (mean 9.4 months).
Rate of relapse was 12% (10/83) at 1 year, 18% (7/39) 
at 2 years, 17% (2/12) at 3 years, and 17% (1/6) at 4 years. 
The overall rate of relapse was 23% (20/87), and the time 
to relapse differed from 3 to 42 months (mean 16 months). 
Disease relapse was not correlated with duration (p = 0.54, 
95% confidence interval = 0.98–1.01), baseline SELENA-
SLEDAI score (p = 0.17, 95% confidence interval = 0.97–
1.16), or CYC conditioning regimen (p = 0.14, 95% 
confidence interval = 0.13–1.31) by Cox regression anal-
ysis. For all 20 relapse events, 15 had suspected underly-
ing causes (infection in nine patients, drug withdrawal in 
five patients, and bone fracture in one patient). Only a 
minority of patients (7/87, 8%) had no clinical response 
to allogeneic MSCT during 1–4 years of follow-up.
Eighteen of the patients who did not have sustained 
responses or had relapse after the first MSC infusion 
were treated with subsequent infusions of the same dose, 
but not necessarily the same type of infusion, each time, 
without CYC for pretreatment (13 had previously been 
CYC pretreated). The average time of the second MSCT 
is 10.0 ± 6.3 months (3–28 months). Sixteen patients 
received two transplants (4 received BM followed by UC, 
1 received UC followed by BM, and 11 received two UC 
transplants), one patient received three transplants (all 
UC), and one patient received four transplants (two BM 
followed by two UC) from different donors. Two patients 
died; two other patients achieved complete clinical remis-
sion 3 and 6 months after the second MSCT; seven patients 
showed response but did not reach the criteria of complete 
clinical remission, while an additional seven patients were 
refractory to multiple doses or underwent lupus relapses.
Serum albumin and complement 3 levels improved 
after MSCT. Levels of serum albumin normalized at 
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3 months posttransplantation for most patients and 
remained stable thereafter [mean (SD): 2.56 (0.47) g/dl 
before MSCT, 2.92 (0.48) g/dl at 3 months, 3.14 (0.42) g/dl 
at 6 months, 3.38 (0.50) g/dl at 1 year, 3.59 (0.56) g/dl at 2 
years, 3.50 (0.57) g/dl at 3 years, 3.83 (0.66) g/dl at 4 years, 
p < 0.001 at 3 months, 6 months,1 year, and 2 years, 
p = 0.010 at 3 years] (Fig. 2A). Complement 3 increased 
at 3 months post-MSCT (p = 0.001) and achieved nearly 
normal levels at 6 months visit [mean (SD): 49.05 (16.50) 
mg/dl before MSCT, 62.13 (21.61) mg/dl at 3 months, 
70.67 (21.35) mg/dl at 6 months, 76.06 (21.75) mg/dl at 
1 year, 80.13 (17.06) mg/dl at 2 years, 87.71 (17.90) mg/dl 
at 3 years, 90.00 (20.83) mg/dl at 4 months, p < 0.001 at 
6 months, 1 year, and 2 years, p = 0.002 at 3 years] (Fig. 2B). 
Serum anti-dsDNA antibody decreased significantly at 3 
and 6 months of follow-up [mean (SEM): 543.4 (110.8) 
U/ml before MSCT, 398.2 (98.9) U/ml at 3 months, 480.1 
(125.6) U/ml at 6 months, 475.5 (163.6) U/ml at 1 year, 
394.0 (110.9) U/ml at 2 years, p = 0.021 at 3 months, 
p = 0.019 at 6 months] (Fig. 2C), along with decreased 
antinuclear antibody (ANA) at 6 months [p = 0.045, mean 
(SEM): 5.81 (0.44) before MSCT, 4.99 (0.46) at 3 months, 
4.86 (0.59) at 6 months, 4.37 (0.64) at 1 year, 3.95 (0.68) 
at 2 years] (Fig. 2D).
SELENA-SLEDAI scores significantly improved for 
up to 4 years after MSCT (Fig. 3A). Renal involvement 
assessed by 24-h proteinuria improved 6 months, 1 year, 
2 years, 3 years, and 4 years after MSCT [mean (SD): 
2.71 (1.19) g before MSCT, 2.02 (1.10) g at 1 month, 1.79 
(1.29) g at 3 months, 1.52 (0.960) g at 6 months, 1.52 
(1.01) g at 1 year, 1.53(1.02) at 2 years, 1.12 (1.02) g at 
3 years, 1.32 (1.52) g at 4 years] (Fig. 3B). For those with 
abnormal levels of serum creatinine and urea nitrogen at 
baseline (n = 31), these index improved significantly 1 
and 2 years after MSCT [mean (SEM), for serum creati-
nine: 1.98 (0.26) mg/dl versus 2.28 (0.19) mg/dl at 1 year, 
n = 31, p = 0.029; 2.02 (0.25) mg/dl versus 2.37 (0.26) mg/dl 
at 2 years, n = 22, p = 0.026; for serum urea nitrogen: 
11.73 (0.91) mol/l versus 18.27 (1.70) mol/l at 1 year, n = 31, 
p < 0.001; 11.07 (1.01) mol/l versus 17.35 (2.11) mol/l at 
2 years, n = 21, p < 0.001] (Fig. 3C, D). Glomerular fil-
tration rate (GFR) was calculated in 63 patients before 
MSCT, in which 10 patients had normal levels at base-
line and did not have additional assessment after MSCT. 
GFR for the other 53 patients improved significantly 
1 year after MSCT [mean (SD), 51.5 (21.5) ml/min before 
MSCT, 63.4 (26.2) ml/min at 1 year, p < 0.01]. For 25 
patients who conducted GFR at 2 years of follow-up, we 
also found a statistical improvement [mean (SD), 56.1 
(20.6) ml/min before MSCT, 67.8 (28.6) ml/min at 2 years, 
p = 0.03].
Thirty-six patients had refractory hypohemoglobin-
emia, in which 29 combined with severe thrombocy-
topenia. Hemoglobin and platelet counts were found 
increased since 1 month after MSCT and remained stable 
for more than 2 years (Fig. 4). Seizure did not recur in 
three patients following MSCT, in parallel with ame-
lioration of lupus nephritis and satisfactory control of 
hypertension. Aminotransferase levels remained normal 
in three patients with autoimmune hepatitis after MSC 
infusion including no recurrence of upper gastrointestinal 
hemorrhage in one patient who had liver cirrhosis and 
experienced two episodes of severe hemorrhage 1 month 
before MSCT. Diffuse alveolar hemorrhage (DAH) asso-
ciated with active lupus in three patients was satisfac-
torily controlled by MSC transplantation. An additional 
Figure 1. Cumulative survival and remission after MSCT. Probability of survival (A) and clinical remission (B) in lupus patients 
undergoing mesenchymal stem cell transplantation (MSCT) by Kaplan–Meier survival analysis. “No. at Risk” refers to number of 
patients at that time point.
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two patients received MSCT for interstitial pneumonia: 
one had improvement in clinical symptoms, and the other 
required a second MSCT for unsatisfactory control of the 
disease. No differences were found in disease remission, 
SELENA-SLEDAI score, proteinuria, and serum albumin 
between those with or without CYC pretreatment, those 
infused with bone marrow- or umbilical cord-derived 
MSCs (Figs. 5 and 6).
The dose of prednisone was tapered at 5–10 mg 
every 2 weeks in the first month following transplanta-
tion according to clinical status and laboratory indica-
tors of disease amelioration. During 4 years of visits, all 
the patients underwent steroid and immunosuppressive 
drugs tapering after MSC transplantation. Six of 82 (7%) 
patients had discontinued immunosuppressants and only 
took prednisone at 5–10 mg/day for maintenance therapy. 
Dose of immunosuppressive drugs were tapered to main-
tenance level (CYC 0.6–0.8 g/2–3months, or mycophe-
nolate mofetil 0.5 g/day or leflunomide 10 mg/day) for 
53/82 (65%) patients at the last follow-up (Table 2).
Safety
Five of 87 patients died after MSCT, all judged to 
be from non-treatment-related events. One patient died 
3 months after the second transplantation, associated with 
acute gastroenteritis and heart failure. A second patient 
succumbed to a disseminated pulmonary infection and 
uncontrolled lupus nephritis 6 months after MSCT. One 
patient had a lupus relapse 8 months after MSC infusion 
with pulmonary hypertension and died from right-sided 
heart failure. A fourth patient had had a remission since 
3 months of follow-up with a significant decrease in pro-
teinuria and normalized serum albumin, but her disease 
relapsed 8 months later; she underwent a second MSCT 
and also achieved remission, but she died from pulmo-
nary embolism 9 months after the second MSCT without 
evidence of active SLE. The fifth patient, who had active 
lupus with malar rash, arthralgia, uncontrolled hyperten-
sion, rapid deterioration of renal function, hypoproteine-
mia, and severe proteinuria, died 1 week post-MSCT from 
uncontrolled progressive disease and acute heart failure.
Two patients experienced diarrhea 3 and 4 months 
after MSCT, respectively. Two additional patients had 
moderate herpesvirus infection at 1 and 6 months after 
MSCT, respectively. One patient experienced agranulo-
cytosis and oral fungus infection 7 days after CYC pre-
treatment, and her condition improved after conventional 
therapy. Tuberculosis infection in the lung was found in 
Figure 2. Serology and complement levels before and after (MSCT). Serum albumin (A) and complement C3 (B) increased after 
MSCT. Serum anti-double-strand DNA (dsDNA) antibody and antinuclear antibody (ANA) declined after MSCT (C and D). The black 
bars represent mean value. *p < 0.05, **p < 0.01.
ALLOGENEIC MSC TRANSPLANTATION IN REFRACTORY SLE 2273
Figure 3. Disease activity score and serum measurements following MSCT. Systemic lupus erythematosus (SLE) Disease Activity 
Score (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease 
Activity Index; SELENA-SLEDAI) (A) and proteinuria (B) improved before and after MSCT. Serum urea nitrogen (C) and creatinine 
(D) decreased significantly 1 and 2 years after MSCT. The black bars represent mean value. *p < 0.05, **p < 0.01.
Figure 4. Hemoglobin and platelet counts following MSCT. Hemoglobin level (A) and platelet (PLT) counts (B) increased signifi-
cantly after MSCT. The black bars represent mean value. *p < 0.05, **p < 0.01.
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one patient 9 months after MSCT, and she was given anti-
tuberculosis drugs for 9 months. One patient had bone 
fracture on L3 in an accident 2 months after her third 
MSCT. One patient underwent myocardial infarction 14 
months after MSCT and responded to treatment by per-
cutaneous coronary intervention (PCI), with no lupus 
relapse. All the adverse events were not considered to be 
related to the MSC infusions.
DISCUSSION
Systemic delivery of autologous or allogeneic MSCs 
has been evaluated in patients with graft versus host 
disease (GVHD), acute myocardial infarction, ischemic 
stroke, etc., based on their properties of immunomodula-
tion and tissue repair (9,16,17). Our preliminary small-
scale and short-term data suggested that allogeneic bone 
marrow- or umbilical cord-derived MSC transplantation 
may be a feasible and safe therapy for refractory SLE 
patients (19,33). However, a larger-scale and longer term 
study is required to assess safety and efficacy.
Among the 87 SLE patients enrolled, 73 (84%) had 
nephritis, and a small portion had other systemic involve-
ments. The overall survival rate was 94% (82/87), with a 
mean follow-up duration of 27 months. Five patients died 
of active lupus that was refractory to conventional thera-
pies as well as MSCT. No major toxicity related to MSCT 
was observed, although some adverse events may have 
occurred, associated with the CYC conditioning regi-
men. The study met its primary objective demonstrating 
the safety of allogeneic MSCT during the infusion and 
long-term follow-up. In addition, the results of this study 
provided evidence that allogeneic MSCT demonstrated 
clinical efficacy in SLE patient refractory to conventional 
therapies by the decline of disease activity score, improve-
ment of renal function, and systemic involvement.
This study is the first to report long-term follow-up 
data for allogeneic MSCT in refractory SLE patients. 
With a similar mean follow-up time (27 months) com-
pared to two studies of autologous stem cell transplan-
tation (ASCT) for SLE (29 months and 26 months, 
Figure 5. Effect of cyclophosphamide (CYC) on disease and serum parameters. No differences in disease remission (A), SELENA-
SLEDAI score (B), proteinuria (C), and serum albumin (D) were found between those with or without CYC pretreatment.
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respectively) (2,11), the rate of complete clinical remis-
sion was similar [50% at 4 years in allogeneic MSCT; 
50% at 5 years in ASCT of Burt et al. study (2); 66% at 
6 months in ASCT of Jayne et al. study (11)]. Importantly, 
the overall survival rate was higher in the current study 
(94% compared to 84% and 62% in ASCT, respectively), 
and there was no transplantation-related mortality (0 in 
MSCT compared to 4% and 12% in ASCT, respectively). 
Additionally, the overall rate of relapse was lower (23% in 
MSCT compared to 28% and 32% in ASCT, respectively); 
all indicated that allogeneic MSCT possesses therapeutic 
potential to induce refractory lupus remission and higher 
safety. However, all the three studies were nonrandom-
ized, and it was difficult to compare exactly due to the 
heterogeneous disease manifestation at baseline.
Of 87 patients infused with a single allogeneic MSCT, 
only 8% of patients had no clinical response, suggesting 
that the current infused cell dose (106/kg of body weight) 
Figure 6. Effect of source of MSCs on disease and serum parameters. Comparisons of disease remission (A), SELENA-SLEDAI 
score (B), proteinuria (C), and serum albumin (D) between patients transplanted with bone marrow (BM)- or umbilical cord (UC)-
derived MSCs.
is sufficient to facilitate a clinical effect. We chose a low 
dose of CYC for precondition regimen to inhibit lympho-
cyte activation in these patients. The dose of CYC was 
much lower in MSCT (30 mg/kg) than in ASCT (200 mg/
kg), and white blood counts were not less than 1,000/μl 
after CYC treatment. Furthermore, a part of the popula-
tion was not given CYC pre-MSCT for the severe dis-
ease conditions at baseline. They also responded well to 
MSC infusions, and no difference in disease remission 
was found between those with or without CYC pretreat-
ment after 4 years of visits. Moreover, our previous study 
showed that the addition of CYC could not enhance thera-
peutic effect and immunomodulation in lupus mice (35), all 
suggesting that the clinical effect was not related to CYC.
While the present results provide reassurance regard-
ing the safety and clinical efficacy of allogeneic MSCT for 
refractory SLE, especially for lupus nephritis, more stud-
ies are required to understand the mechanism of action of 
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this approach. Our previous lupus animal study also dem-
onstrated that carboxyfluorescein diacetate succinimidyl 
ester (CFSE)-labeled allogeneic MSCs could home to 
kidney, lung, liver, and spleen tissues of lupus-prone mice 
(8). Meanwhile, MSCs are reported to differentiate into 
functional renal tubular epithelial cells and hepatocytes in 
vitro and in vivo and contribute to tissue repair (18,31). 
Additionally, MSCs exerted complex paracrine and 
endocrine actions including the secretion of growth fac-
tors and cytokines, modulation of immune response, and 
antiapoptotic and anti-inflammatory effects. Our previous 
clinical studies had shown that allogeneic MSC transplan-
tation could upregulate peripheral cluster of differentiation 
4-positive forkhead box P3-positive (CD4+Foxp3+) regula-
tory T-cells in SLE patients (19,33), all of which may con-
tribute to organ repair and immune regulation (22).
As this study was a clinical trial, we were unable to label 
MSCs, and thus, whether a positive response to MSCT is 
associated with specific tissue localization and healing is 
still unclear. Our previous work has shown that inhibition 
of Th2-mediated humoral immunity may also play a role 
in the effectiveness of MSCT (33), and we hypothesize 
that MSCs may play a role individually or synergistically 
in SLE patients. Certainly, further experiment is required 
to investigate the mechanistic issues surrounding the use 
of MSCT.
This study focused on the safety and efficacy of allo-
geneic MSCT for severe and drug refractory SLE patients 
but was not a randomized controlled trial. We could not 
compare quantitatively the effect of MSCT to the con-
ventional treatments with corticosteroids and other 
immunosuppressive drugs. In our opinion, it is difficult to 
design an RCT study in refractory SLE patients. Next, we 
will consider to perform a randomized, double-blind, and 
multicenter-controlled study in China to assess the safety 
and efficacy of MSCT in newly diagnosed SLE patients 
or those without previous formal treatments to further 
examine whether the adding of MSCT is prior to con-
ventional therapies only. In addition, this study involved 
only a single center with patients all being Chinese in eth-
nicity, and thus the results should not be extrapolated to 
SLE patients of other ethnic origins. However, based on 
our long-term follow-up and demonstrated safety profile 
of this cell-based therapy, more clinical trials in multiple 
centers are needed to determine the efficacy of MSCT for 
larger groups of SLE patients.
This trial provides evidence that allogeneic MSCT 
may be performed safely in treating refractory and active 
SLE patients, resulting in disease clinical remission and 
improvement of organ dysfunction. MSCT as a new cell 
therapy could be introduced for treatment of refractory 
and severe SLE patients.
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